1. Home
  2. WNW vs JAGX Comparison

WNW vs JAGX Comparison

Compare WNW & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Meiwu Technology Company Limited

WNW

Meiwu Technology Company Limited

N/A

Current Price

$2.37

Market Cap

4.5M

ML Signal

N/A

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

N/A

Current Price

$3.87

Market Cap

4.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WNW
JAGX
Founded
2018
2013
Country
China
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
4.9M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
WNW
JAGX
Price
$2.37
$3.87
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
51.5K
★ 3.1M
Earning Date
11-04-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 82.42
EPS
★ N/A
N/A
Revenue
N/A
★ $11,511,000.00
Revenue This Year
N/A
$77.78
Revenue Next Year
N/A
N/A
P/E Ratio
$1.14
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.05
$0.20
52 Week High
$13.52
$41.53

Technical Indicators

Market Signals
Indicator
WNW
JAGX
Relative Strength Index (RSI) 45.04 49.80
Support Level $2.30 $0.89
Resistance Level $2.75 $8.00
Average True Range (ATR) 0.13 4.48
MACD 0.01 -0.30
Stochastic Oscillator 8.13 10.26

Price Performance

Historical Comparison
WNW
JAGX

About WNW Meiwu Technology Company Limited

Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Share on Social Networks: